新型三唑类抗真菌药物伏立康唑（UK-109,496）对新出现的及较少见霉菌病原体活性的体外研究。
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
作者信息
Radford S A, Johnson E M, Warnock D W
机构信息
Mycology Reference Laboratory, Public Health Laboratory, Bristol, United Kingdom.
出版信息
Antimicrob Agents Chemother. 1997 Apr;41(4):841-3. doi: 10.1128/AAC.41.4.841.
Abstract
The in vitro activity of voriconazole was compared with that of itraconazole. Eighty-six isolates of pathogenic molds belonging to 23 species were tested by an agar dilution method in High Resolution medium. Voriconazole was more active than itraconazole against a number of hyaline molds, including several Fusarium spp. and Scedosporium prolificans. Voriconazole and itraconazole showed comparable good activity against several hyaline molds, including Penicillium marneffei and Scedosporium apiospermum, and a number of dematiaceous molds, including Bipolaris australiensis, Cladophialophora bantiana, several Exophiala spp., and several Fonsecaea spp. Our results suggest that voriconazole could be effective against a wide range of mold infections in humans.
摘要
将伏立康唑的体外活性与伊曲康唑进行了比较。采用琼脂稀释法在高分辨率培养基中对属于23个种的86株致病霉菌进行了检测。伏立康唑对多种透明霉菌，包括几种镰刀菌属和多育赛多孢，比伊曲康唑更具活性。伏立康唑和伊曲康唑对几种透明霉菌，包括马尔尼菲青霉和尖端赛多孢，以及多种暗色霉菌，包括澳大利亚离蠕孢、班替枝孢瓶霉、几种外瓶霉属和几种瓶霉属，显示出相当的良好活性。我们的结果表明，伏立康唑可能对人类多种霉菌感染有效。
相似文献
1
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.新型三唑类抗真菌药物伏立康唑（UK-109,496）对新出现的及较少见霉菌病原体活性的体外研究。
Antimicrob Agents Chemother. 1997 Apr;41(4):841-3. doi: 10.1128/AAC.41.4.841.
2
In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.新型三唑类药物Syn-2869对新出现及较少见霉菌病原体的体外活性
Antimicrob Agents Chemother. 1999 May;43(5):1260-3. doi: 10.1128/AAC.43.5.1260.
3
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.伏立康唑、伊曲康唑和两性霉素B对机会性念珠菌和暗色真菌的体外杀真菌活性。
J Clin Microbiol. 2001 Mar;39(3):954-8. doi: 10.1128/JCM.39.3.954-958.2001.
4
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.伏立康唑、伊曲康唑和两性霉素B对丝状真菌的体外活性。
J Antimicrob Chemother. 1998 Dec;42(6):741-5. doi: 10.1093/jac/42.6.741.
5
6
In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species.艾沙康唑（BAL4815）、伏立康唑和氟康唑对1007株接合菌、念珠菌、曲霉菌、镰刀菌和赛多孢子菌属菌株的体外抗真菌活性。
Antimicrob Agents Chemother. 2008 Apr;52(4):1396-400. doi: 10.1128/AAC.01512-07. Epub 2008 Jan 22.
7
In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.伏立康唑与伊曲康唑、酮康唑、两性霉素B和灰黄霉素相比，对酵母、霉菌和皮肤癣菌临床分离株的体外评价
Mycoses. 1998 Sep-Oct;41(7-8):309-19. doi: 10.1111/j.1439-0507.1998.tb00344.x.
8
[In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].[真菌和酵母临床分离株对伊曲康唑和伏立康唑的体外敏感性]
Rev Iberoam Micol. 2005 Jun;22(2):105-9. doi: 10.1016/s1130-1406(05)70018-8.
9
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.新型三唑类药物伏立康唑（UK-109,496）对机会性丝状真菌和双相真菌以及常见和新出现的酵母病原体的体外活性。
J Clin Microbiol. 1998 Jan;36(1):198-202. doi: 10.1128/JCM.36.1.198-202.1998.
10
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.伏立康唑（UK-109,496）与其他六种抗真菌药物对多育赛多孢和尖端赛多孢临床分离株的体外活性比较
J Antimicrob Chemother. 1999 Jan;43(1):149-51. doi: 10.1093/jac/43.1.149.
引用本文的文献
1
Targeting fungal lipid synthesis for antifungal drug development and potentiation of contemporary antifungals.以真菌脂质合成作为抗真菌药物研发及增强现有抗真菌药物效果的靶点。
NPJ Antimicrob Resist. 2025 Apr 12;3(1):27. doi: 10.1038/s44259-025-00093-4.
2
Mechanism Underlying Conflicting Drug-Drug Interaction Between Aprepitant and Voriconazole via Cytochrome P450 3A4-Mediated Metabolism.通过细胞色素P450 3A4介导的代谢，阿瑞匹坦与伏立康唑之间存在冲突性药物相互作用的潜在机制。
Yonago Acta Med. 2024 Jan 24;67(1):31-40. doi: 10.33160/yam.2024.02.004. eCollection 2024 Feb.
3
Development and validation of a colorimetric antifungal susceptibility testing method for the dimorphic fungus Talaromyces marneffei.显色法测定二相性真菌马尔尼菲篮状菌抗真菌药物敏感性的方法的建立和验证。
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad111.
4
Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review.EMA 批准的抗真菌药物研发过程中的临床前药代动力学/药效学研究和临床试验：综述。
Clin Pharmacokinet. 2024 Jan;63(1):13-26. doi: 10.1007/s40262-023-01327-2. Epub 2023 Nov 16.
5
Therapeutic drug monitoring and genotyping guide the application of voriconazole in children.治疗药物监测和基因分型指导伏立康唑在儿童中的应用。
Transl Pediatr. 2022 Aug;11(8):1311-1322. doi: 10.21037/tp-22-156.
6
infection of the lumbar vertebrae: A case report.腰椎感染：一例报告。
World J Clin Cases. 2022 Apr 6;10(10):3251-3260. doi: 10.12998/wjcc.v10.i10.3251.
7
Management of pulmonary infection by thoracoscopic surgery in an immunocompetent woman.免疫功能正常女性肺部感染的胸腔镜手术治疗
J Int Med Res. 2020 Jul;48(7):300060520931620. doi: 10.1177/0300060520931620.
8
Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic-pharmacodynamic analysis of tear fluid following oral administration.基于口服后泪液的药代动力学-药效学分析评估系统伏立康唑在马角膜真菌病中的应用
Vet Ophthalmol. 2020 Jul;23(4):640-647. doi: 10.1111/vop.12764. Epub 2020 May 8.
9
A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis.基于群体药代动力学分析的伏立康唑个体化CYP2C19表型指导给药方案
J Clin Med. 2019 Feb 10;8(2):227. doi: 10.3390/jcm8020227.
10
Voriconazole-induced periostitis: a new rheumatic disorder.伏立康唑诱发的骨膜炎：一种新的风湿性疾病。
Clin Rheumatol. 2017 Mar;36(3):609-615. doi: 10.1007/s10067-016-3341-7. Epub 2016 Jul 4.
本文引用的文献
1
Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.新型唑类抗真菌药UK-109496在侵袭性曲霉病实验模型中的疗效
Antimicrob Agents Chemother. 1996 Jan;40(1):86-91. doi: 10.1128/AAC.40.1.86.
2
Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.白色念珠菌临床分离株在体外及小鼠模型体内对氟康唑和伊曲康唑的耐药性比较
Antimicrob Agents Chemother. 1996 Jun;40(6):1342-5. doi: 10.1128/AAC.40.6.1342.
3
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis.在新型隐球菌性脑膜炎小鼠模型中体外唑类药敏性与体内反应的相关性
J Infect Dis. 1993 Aug;168(2):508-10. doi: 10.1093/infdis/168.2.508.
4
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.丝状真菌抗真菌药敏试验标准化的比较与协作评估
Antimicrob Agents Chemother. 1995 Feb;39(2):314-9. doi: 10.1128/AAC.39.2.314.
5
Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient.多育赛多孢，一种多重耐药真菌，源自一名英国艾滋病患者。
J Infect. 1995 Mar;30(2):153-5. doi: 10.1016/s0163-4453(95)80011-5.
6
Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method.通过肉汤微量稀释法增加致病丝状真菌接种量对抗真菌剂最低抑菌浓度的影响。
J Clin Microbiol. 1995 May;33(5):1302-7. doi: 10.1128/jcm.33.5.1302-1307.1995.
7
Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients.体外药敏试验结果与临床反应的相关性：艾滋病患者唑类治疗的一项研究。
J Antimicrob Chemother. 1995 Jun;35(6):793-804. doi: 10.1093/jac/35.6.793.
8
Disseminated infection with Fusarium in recipients of bone marrow transplants.骨髓移植受者的播散性镰刀菌感染。
Rev Infect Dis. 1991 Nov-Dec;13(6):1077-88. doi: 10.1093/clinids/13.6.1077.
9
Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies.由博伊德氏霉样真菌（皮炎外瓶霉）引起的内脏真菌感染。体外药敏研究。
Am J Med. 1976 Nov;61(5):632-40. doi: 10.1016/0002-9343(76)90141-8.
Zotero 插件